Yahoo Web Search

  1. MBVX-1.01% ("MabVax" or the "Company"), a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of ...

  2. MRUS-1% a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics(R)), today announced that it has agreed to sell 3.1 million shares of ...

  3. MGNX-1.02% a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced ...

  4. AnaptysBio is a clinical-stage antibody development company focused on unmet medical needs in inflammation. The Company's lead drug candidate is ANB020, an inhibitor of interleukin-33 ...

  5. THOUSAND OAKS, Calif., Feb. 14, 2018 /PRNewswire/ -- Amgen AMGN+2.81% today announced that the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will review data ...

  6. Press Release Sun Pharma Announces Twelve Tildrakizumab Abstracts to be Presented at American Academy of Dermatology 2018 Annual Meeting Published: Feb 12, 2018 8:12 am ET Data Presentations Highlighting Pivotal

  7. LONDON, UK / ACCESSWIRE / February 12, 2018 / Active-Investors.com has just released a free research report on Pieris Pharmaceuticals, Inc. PIRS+6.42% ("Pieris"). If you want access to this ...

  8. Press Release LakePharma Announces Expansion And New MicroBiomanufacturing Center In Hopkinton, MA Published: Feb 12, 2018 1:00 pm ET SOUTH SAN FRANCISCO, Calif

  9. One drug that may be able to successfully help patients with solid tumors, however, is Rova-T, an investigational antibody-drug conjugate that AbbVie acquired for $5.8 billion up front ...

  10. CNW Group Merck and Pfizer Provide Update on Phase III JAVELIN Lung 200 Trial of Avelumab Monotherapy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer Published: Feb 15, 2018 8:33 am ET

  1. 12345184 results